nAMD, DR, and DME: Advances in Sustained Delivery Strategies
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
nAMD, DR, and DME: Advances in Sustained Delivery Strategies
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Making Sense of Emerging Retinal Therapies: Expert Perspectives and Clinical Implications
This activity is supported by educational grants from 4D Molecular Therapeutics; Merck & Co., Inc.; Ocugen, Inc.; Ocular Therapeutix, Inc.; Oculis; and REGENXBIO Inc.
Rapid Response from Clinical Trials at the Summit: Translating New Evidence Into Retinal Care
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
nAMD and DME: Translating Biomarker Insights Into Sustained Care
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
nAMD and DME: Clinical Biomarkers for Targeted, Durable Care
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Slowing GA Progression: Tailoring Therapy to Patient Needs
This activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Topcon Healthcare, Inc.
MacTel Moves Forward: Sustained Innovation for Lasting Impact
This activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.
nAMD, DR, and DME: Reducing Treatment Burden With Long-Acting Drug Delivery Systems
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
DME and nAMD: Using Clinical Biomarkers to Optimize Outcomes in Real-World Cases
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Diabetic Macular Edema: Rethinking Response and Revising Treatment With Corticosteroid Therapy
This activity is supported by an educational grant from AbbVie Inc.
Retina360: Focus on New Therapies
This activity is supported by educational grants from 4D Molecular Therapeutics; Alkeus Pharmaceuticals, Inc.; ANI Pharmaceuticals, Inc.; Harrow, Inc.; Merck & Co., Inc.; Oculis; and REGENXBIO Inc.